What Bonesil D Flas Treats: Main Uses and Benefits

Bonesil D Flas is a medication that may be part of symptomatic management in patients experiencing specific hormonal imbalances that result in symptoms related to systemic imbalance. Its therapeutic applications are applied across domains where additional symptomatic support is needed.

---

Core Therapeutic Areas

The medicine is commonly used across conditions presenting with acute episodes and is commonly used to help with primary and secondary adrenocortical insufficiency (Addison’s disease) and Salt-Losing Adrenogenital Syndrome. These are conditions involving episodic or fluctuating manifestations that require short-term symptomatic assistance.

“The therapy contributes to easing the overall symptom burden associated with systemic or localized discomfort.”

In these clinical scenarios, Bonesil D Flas is relevant for easing symptoms linked to organ-specific functional stress. It supports the patient during difficult episodes by assisting with maintaining functional stability and contributing to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for symptoms that create noticeable physiological strain

Regulatory References

1. DailyMed (National Library of Medicine) Label Overview

Official Eligibility Profile: Who Can and Cannot Use Bonesil D Flas?

This section describes the regulatory criteria governing the use of Bonesil D Flas (Calcium Carbonate, Colecalciferol).

Contraindicated Populations (Must Not Use): Use is strictly contraindicated for patients presenting with an excess of the active components, including Hypercalcaemia, Hypercalciuria, or Hypervitaminosis D. The medicine is also prohibited in individuals with severe renal impairment, a history of Nephrolithiasis (kidney stones), or known hypersensitivity to the active substances or excipients, such as soya or peanut.

Age-Related Eligibility: Use is established for Adults and Older Adults. The high-dose combination product is not intended for use in Children and Adolescents under 18 years of age.

Restricted and Conditional Use: Use is restricted and requires caution in patients with non-severe renal impairment or sarcoidosis, as these groups necessitate regular monitoring of serum calcium and phosphate levels. For pregnant women, use is conditional upon documented deficiency and is subject to a strict maximum daily dose limit defined by official labeling.

The interaction profile for Bonesil D Flas, a combination of Calcium Carbonate and Colecalciferol (Vitamin D3), is defined by specific pharmacokinetic and pharmacodynamic patterns documented in official government regulatory labeling.

Interaction Category	Interacting Agents and Official Pattern
Absorption Interference	Tetracycline and Quinolone antibiotics: Calcium reduces the absorption and plasma concentration of these antibiotics. Bisphosphonates and Thyroid hormones also have reduced absorption when co-administered.
Mineral Balance Effects	Thiazide diuretics: These agents reduce calcium excretion, formally increasing the risk of hypercalcaemia. Cardiac Glycosides: Co-administration increases the risk of cardiac toxicity if hypercalcaemia is present.
Metabolic Alteration	Rifampicin, Phenytoin, and Barbiturates: These substances increase the metabolic clearance of the Colecalciferol component, which is documented to reduce its activity.
Food Interaction	Oxalic Acid and Phytic Acid (in certain foods) are documented to inhibit calcium absorption and require specific timing separation from administration.

Administration Constraints: Regulatory documents establish specific timing constraints. For agents like tetracyclines, quinolones, bisphosphonates, and certain dietary items, separation windows of two to six hours are formally required to minimize absorption interference. A specific note exists for elderly patients on cardiac glycosides or diuretics, advising the need for enhanced clinical monitoring due to heightened interaction risk. The documented interactions fundamentally define the requirements for dose spacing and monitoring when co-administered with numerous medicinal products.

Bonesil D Flas is composed of calcium carbonate and cholecalciferol (Vitamin D3). Its mechanism of action is mediated by both components, primarily modulating mineral homeostasis.

Calcium Carbonate Mechanism

Calcium carbonate dissociates into ionized calcium ( Ca^2+) in the acidic environment of the stomach. Ca^2+ is then absorbed in the small intestine via active transport, which is dependent on Vitamin D, and via passive diffusion.

Cholecalciferol Mechanism

Cholecalciferol (D3) is a prohormone. It undergoes 25-hydroxylation in the liver to form 25-hydroxyvitamin D3 (calcifediol), which is then transported to the kidney. In the kidney, 1-alpha -hydroxylase catalyzes the formation of the biologically active metabolite, 1,25-dihydroxyvitamin D3 (calcitriol).

Calcitriol acts as a ligand for the nuclear Vitamin D Receptor (VDR), a transcription factor present in various tissues, including the intestine and bone. The calcitriol-VDR complex translocates to the nucleus, binding to Vitamin D response elements (VDREs) on target genes. This gene transcription modulation leads to the increased synthesis of proteins involved in intestinal absorption of calcium and phosphate. In the bone, calcitriol facilitates the mobilization of calcium and phosphate into the systemic circulation by regulating osteoclast activity.

System-Level Consequences

The synergistic actions of exogenous calcium supply and VDR-mediated pathways increase plasma calcium and phosphate concentrations, directly contributing to the systemic modulation of mineral balance.

How to Use Bonesil D Flas

Bonesil D Flas is an orodispersible tablet administered through the oral route to provide combined calcium and Vitamin D supplementation. Usage follows established dosing and administration principles to ensure consistent intake for adult populations.

---

Standard Regimens and Frequency

Administration follows a standard regimen for adults and older adults, typically encompassing 1 to 2 tablets per day. This daily range means the medicine is usually taken once daily or in a divided twice-daily frequency, depending on the number of tablets prescribed by a healthcare professional. Each tablet delivers a fixed-dose combination of 1,500 mg Calcium Carbonate (equivalent to 600 mg elemental Calcium) and 400 IU Colecalciferol.

---

Administration Technique and Context

Procedural Requirement	Instruction
Timing in Relation to Meals	Administration is recommended preferably after meals (postprandially).
Tablet Handling	The tablet must dissolve completely in the mouth on the tongue; it should not be swallowed whole.
Final Step	After the tablet has fully dissolved, the instructions specify to swallow a glass of water

This specific technique is required for the correct function of the orodispersible form. Furthermore, it is recommended to avoid consumption of foods high in oxalic or phytic acid within two hours of intake, as this can affect absorption. The therapy is commonly prolonged, requiring long-term adherence to the daily schedule.

Research Evidence: Overview of Studies for Bonesil D Flas

This section provides a summary of the available research base for the combination of Calcium Carbonate and Colecalciferol (Vitamin D3). The information describes the structure and findings of research on the combination, consistent with regulatory guidance on evidence presentation. Research describes group patterns and does not determine whether an individual will respond similarly.

Evidence for Supplementation in Bone Health and Osteoporosis Management

Research for this product was evaluated in multiple Randomized Controlled Trials (RCTs) and systematic reviews that explored outcomes related to skeletal structure and exploring outcomes related to combined mineral and vitamin deficiency. The evidence base was studied for the population of people with osteoporosis and those considered at risk for fractures.

Researchers primarily monitored outcomes related to changes in Bone Mineral Density (BMD), a measured factor. Studies also focused on tracking the reported incidence of clinical fractures (such as hip and non-vertebral fractures) and measuring blood levels of the Vitamin D biomarker, serum 25-hydroxyvitamin D [25(OH)D]. These trials included older adults, particularly postmenopausal women, and also focused on patients who were either institutionalized or living independently in the community.

Studies reported measurements of both BMD and the Vitamin D biomarker. Research describes that changes in these physiological indicators were observed in the studies over the defined time periods. Findings were mixed across the entire body of evidence, and the reported patterns often varied depending on the specific characteristics of the populations studied.

Long-Term Studies and Follow-Up Duration

Studies exploring outcomes was observed in trials with follow-up durations that range across the intermediate term, typically lasting from 18 months to over 3 years. While aggregated data may include observations spanning up to seven years, long-term effects are not fully established across the entire evidence base. This means that information regarding the persistence of the outcomes observed over many years is still emerging.

What Remains Uncertain About the Research

One key challenge is the inconsistency of findings across the different clinical trials. Some large trials focusing on community-dwelling adults have reported different outcomes when compared to the aggregated results of meta-analyses, indicating that evidence quality varies across studies. Furthermore, comparative evidence is lacking for many direct comparisons against other specific calcium and Vitamin D supplement formulations. These are limitations that researchers continue to address.

Common questions about Bonesil D Flas (FAQ)

---

Q: Why is the 'D Flas' part in the name important?

The name highlights the medicine's composition and delivery method. The 'D' stands for the Colecalciferol (Vitamin D3) component, which is crucial for absorbing calcium. The 'Flas' indicates it's an orodispersible tablet, a specialized form designed to dissolve rapidly on the tongue. This specific delivery system is a key characteristic of the product described in the official documents.

Q: Is it normal to feel a mild stomach upset after starting Bonesil D Flas?

According to official product information, gastrointestinal effects such as flatulence, constipation, and abdominal pain are documented as rare side effects. This means they are expected to affect no more than 1 in every 1,000 people. Regulatory documents primarily focus on requiring healthcare professionals to monitor adverse reactions.

Q: Is Bonesil D Flas a type of vitamin or a prescription drug?

Bonesil D Flas is formally classified as a fixed-dose oral medicinal product that combines the mineral Calcium Carbonate and the vitamin analogue Colecalciferol (Vitamin D3). It belongs to the therapeutic group that influences calcium and bone metabolism. This classification defines the medicine's role within calcium and bone metabolism therapy.

Q: How long do most people need to stay on Bonesil D Flas?

Official regulatory guidelines describe the therapy using this medicine as prolonged. This indicates that the regimen often requires long-term adherence to a daily schedule. The specific duration of the therapy is determined on an individual basis by the prescribing healthcare professional.

Q: Are there different strengths of Bonesil D Flas available?

The official labeling for this product lists only one available fixed strength. Each orodispersible tablet delivers a combination of 1,500 mg Calcium Carbonate and 400 IU Colecalciferol (Vitamin D3). There are no other strengths of Bonesil D Flas listed in the regulatory documents.

Q: Is Bonesil D Flas known to interact with common pain relievers?

Official regulatory documentation for this product does not specifically list common over-the-counter pain relievers, such as NSAIDs or acetaminophen, as interacting medicines. However, the medicine is documented to interfere with the absorption of certain classes of antibiotics and other prescription drugs. Information regarding all concurrent treatments is essential for healthcare professionals when reviewing the interaction profile.

Q: Can Bonesil D Flas be taken at night?

Official instructions recommend that the medicine be administered preferably after meals (postprandially). Regulatory documents do not prohibit taking it in the evening or at night, as long as this timing is consistent with taking it following a meal.

Q: Will Bonesil D Flas affect my blood test results?

Yes, the components of Bonesil D Flas are known to affect blood chemistry. Official warnings indicate that during long-term treatment, the monitoring of serum calcium levels and kidney function is documented as necessary. The purpose of this monitoring is to assess the risk of mineral imbalance.

Q: How does Bonesil D Flas compare to other medicines for the same condition?

Official research overviews indicate that comparative evidence is lacking for many direct comparisons against other specific calcium and Vitamin D supplement formulations. Therefore, the official regulatory information presents the documented effects of this medicine alone.

Q: What happens if I accidentally take more than the instructed amount?

Accidental high exposure is associated with an increased risk of significant adverse reactions. Regulatory information documents that this may include conditions like severe hypercalcaemia (excess calcium in the blood) and milk-alkali syndrome. Official information documents these as risks associated with overdose, but specific emergency instructions are outside the scope of general public information.

Q: Can I take Bonesil D Flas if I have kidney issues?

The official eligibility profile depends on the severity of the kidney issues. Use is strictly contraindicated (prohibited) for patients with severe renal impairment (kidney function issues). For those with non-severe impairment, the medicine may be used, but caution and regular monitoring of calcium levels are explicitly documented as necessary.

Q: Is Bonesil D Flas safe to use long-term?

The therapy is commonly prolonged, but regulatory documents stipulate specific conditions for long-term use. This requires explicit and regular monitoring of serum calcium levels and kidney function to manage the documented risk of mineral imbalance.

Q: Can men use Bonesil D Flas, or is it just for women?

Official eligibility documents establish the medicine's use for the general population of Adults and Older Adults. The use of this product is not restricted by gender, although the research base often includes a focus on postmenopausal women.

Q: Is the efficacy of Bonesil D Flas proven by clinical trials?

Studies and official information indicate that clinical research includes multiple trials where changes in physiological indicators like Bone Mineral Density (BMD) were observed. However, the evidence is officially noted to be mixed and inconsistent across all studies. The official regulatory description respects the uncertainty, noting that evidence quality varies and findings have been mixed.

Q: What is the chemical name for Bonesil D Flas?

The medicine is identified by its two active components: Calcium Carbonate and Colecalciferol (Vitamin D3). These are the chemical names for the mineral salt and the Vitamin D analogue, respectively.

Q: What is the expected outcome from taking Bonesil D Flas for its intended use?

The intended action of the medicine is to contribute to robust bone mineralization and help achieve systemic mineral balance. Research describes the expected physiological indicators, such as changes in Bone Mineral Density (BMD) and blood levels of Vitamin D.

Q: Does Bonesil D Flas affect my heart rate?

While changes in heart rate are not listed as a common direct side effect, the medicine has a documented effect on calcium levels. Excessive calcium in the blood (hypercalcaemia) is noted to increase the risk of cardiac toxicity, especially in certain patient groups or when combined with specific heart medicines.

Q: How do I know if Bonesil D Flas is actually working for me?

The medicine is designed to influence measurable indicators that can be clinically monitored. These include Bone Mineral Density (BMD) and blood levels of serum calcium and the Vitamin D biomarker. These indicators are typically tracked by healthcare professionals to assess the product’s effect.

Q: I forgot a dose—what is the general guidance?

According to official product information, if a dose is forgotten, the general guidance is to skip the missed dose entirely. The patient should then continue with the next scheduled dose at the usual time. Do not take a double dose or extra amount to compensate for the forgotten one.

Q: Does Bonesil D Flas contain any dairy ingredients?

Based on the official list of excipients (inactive ingredients), regulatory documentation does not list any dairy-based ingredients. Only specific excipients such as soya and peanut are mentioned as formal contraindications due to hypersensitivity.

Q: Does Bonesil D Flas interact with alcohol?

Regulatory documents do not contain a specific warning or contraindication regarding the use of alcohol with this medicine. The official interaction profile primarily focuses on prescription drugs and foods containing oxalic or phytic acid.

Q: Can Bonesil D Flas be taken with multivitamins?

Due to the mechanism of action, the calcium component may interfere with the absorption of other minerals, such as iron or zinc, that are often present in multivitamins. Because of this potential interference, a time separation between administrations is generally recommended to avoid potential absorption issues.

Q: Does Bonesil D Flas contain gluten?

Based on the list of excipients (inactive ingredients), official regulatory documentation indicates that the medicine does not contain gluten.

Q: What is the general safety profile of Bonesil D Flas for people with liver issues?

Official documents do not identify specific warnings or required dose adjustments necessary for patients with liver impairment. Warnings and cautions are primarily specified for conditions affecting mineral balance, such as renal (kidney) impairment and hypercalcaemia.

Q: Are there any specific warnings about driving or operating machinery while on Bonesil D Flas?

According to regulatory documents, based on the product's known side effect profile, Bonesil D Flas is not expected to affect the ability to drive or safely operate machinery.

Q: Can Bonesil D Flas make me feel dizzy?

Dizziness is not listed as a documented side effect (such as uncommon or rare) in the official adverse reaction tables for this medicine. The officially noted side effects primarily involve the digestive system or mineral metabolism.

Q: Are there any specific warnings for people with diabetes using Bonesil D Flas?

Official warnings and contraindications do not specify a precaution or restriction for people with diabetes. The warnings are concentrated on conditions that affect mineral and calcium balance, such as kidney impairment.

How to Store and Dispose of Bonesil D Flas

Bonesil D Flas must be stored according to the requirements defined in its official regulatory labeling to maintain stability.

Official Storage Requirements

Condition	Regulatory Mandate
Temperature	Store at a temperature not exceeding 30 C (86 F). Do not freeze.
Protection	Keep the product in the original package to protect from moisture and light.
Safety	Keep out of the sight and reach of children at all times.
Shelf-life	Do not use the medicine after the expiration date (EXP) printed on the packaging.

Disposal Instructions

Unused or expired Bonesil D Flas must not be discarded into household garbage or poured down wastewater. The official disposal instruction requires that all unwanted product be returned to a designated pharmacy collection point or specialized pharmaceutical waste program. This procedure is mandatory to ensure appropriate environmental handling of the medicine.